Pfizer (NYSE:PFE) has signed a co-development and license deal with Medicus Pharma for an early clinical-stage ...
Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient in a trial suffered a liver injury potentially caused by the drug. The ...
Pfizer is playing catch-up in the crowded field of obesity medicines, but it hoped to compete with a daily pill alternative to currently available injectable GLP-1 products. Instead, Pfizer is ...
Add Yahoo as a preferred source to see more of our stories on Google. Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10, 2025, in New York. (AP Photo/Yuki Iwamura) Pfizer ...
What comes to mind when you hear the word cancer? It may be surprising to learn there are many different definitions. That’s because cancer is not a single disease, but rather hundreds of different ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and ...
Pfizer (NYSE:PFE) has named James List, a former Johnson & Johnson (NYSE:JNJ) executive, as the company’s new chief internal medicine officer to boost the company's efforts in obesity drug development ...
Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday that ...
Pfizer signage is displayed at the Pfizer NYC Headquarters, Thursday, April 10, 2025, in New York. (AP Photo/Yuki Iwamura) (Yuki Iwamura, Copyright 2025 The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results